Physician profile
Harmon A Smith
NPI 1215028253
$5,506.18
in general payments reported to CMS, 2019-2025
37 companies · $1,485 in 2025
The $1,485 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $287 · 2020: $63.12 · 2021: $284 · 2022: $645 · 2023: $1,316 · 2024: $1,427 · 2025: $1,485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,227.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $651.34 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $605.70 | 2022-2025 | Vraylar |
| Amgen INC. | $524.63 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Astrazeneca Pharmaceuticals Lp | $399.41 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $386.47 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $383.30 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2, Freestyle Freedom Lite |
| Xeris Pharmaceuticals, INC. | $354.10 | 2021-2024 | Gvoke Hypopen |
| Pfizer INC. | $335.67 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $329.02 | 2021-2025 | |
| Lilly USA, LLC | $275.80 | 2021-2025 | Mounjaro, Jardiance, Kisunla |
| Otsuka America Pharmaceutical, INC. | $166.18 | 2023-2024 | Rexulti |
| Astellas Pharma US INC | $101.54 | 2024 | Veozah |
| Shield Therapeutics INC | $88.26 | 2023-2025 | Accrufer |
| Sanofi-Aventis U.S. LLC | $82.13 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $78.36 | 2025 | Cobenfy |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harmon Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.